Prognosis of decompensated heart failure: role of NT-proBNP

Susana Ferreira1, Rui Almeida, Hector Guerrero

  • 1Departamento de Medicina, Hospital São João, Semiótica Clínica, Porto, Portugal. susanaferreira14@hotmail.com

Insights

N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and their changes during hospitalization predict outcomes in patients with decompensated heart failure (HF). Lower NT-proBNP levels at discharge and a significant decrease during hospitalization are associated with better prognosis.

Area of Science:

  • Cardiology
  • Biomarkers
  • Heart Failure Research

Background:

  • Natriuretic peptides are established prognostic markers in heart failure (HF).
  • NT-proBNP (N-terminal pro-B-type natriuretic peptide) role in predicting outcomes in decompensated HF requires further evaluation.

Purpose of the Study:

  • To assess the predictive value of NT-proBNP levels and their variation during hospitalization for outcomes in patients with decompensated HF.

Main Methods:

  • Analysis of 304 patients admitted with decompensated HF.
  • Two NT-proBNP measurements (admission and discharge) were taken.
  • Patients were followed for up to 6 months, with the primary endpoint being death or readmission.

Main Results:

  • A significant decrease in median NT-proBNP levels was observed during hospitalization (7006 to 3796 pg/ml).
  • NT-proBNP levels at discharge and the variation during hospitalization independently predicted prognosis after adjustment for clinical factors.
  • Higher NT-proBNP at discharge and increasing levels during hospitalization were associated with worse outcomes.

Conclusions:

  • NT-proBNP levels at discharge and their change during hospitalization are valuable independent predictors of outcome in decompensated HF.
  • These findings support the clinical utility and applicability of NT-proBNP monitoring in managing HF patients.
Abstract

Related Concept Videos

Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...